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Background: Japanese Encephalitis (JE) is a mosquito-borne
disease caused by JE virus belongs to the family Flaviviridae. In Asia
approximately 68,000 clinical cases among 10,000 deaths occurs
every year. Although symptomatic JE is rare, the case-fatality rate
among those with encephalitis can be as high as 30%. Permanent
neurologic or psychiatric sequelae can occur in 30%–50% of those
with encephalitis. The risk is highest in children aged 1-15 years,
in rural areas and in the monsoon/post monsoon season.
JE vaccine (JENVACR) development is a collaborative project
between Bharat Biotech International Ltd, Hyderabad, India and
National Institute of Virology, Pune, India.
Methods & Materials: Virus strain (821564-XY) used in vac-
cine development which is isolated from the endemic region of
Kolar, Karnataka, India. Theworld’s ﬁrst fully-integrated, single use
bioreactor used for the production of JE vaccine using Vero cell
line. Puriﬁcation is performed using chromatography techniques.
Formulation has been carried out with alluminium hydroxide gel.
Results: Non-clinical toxicology studies were conducted in lab
animals and the vaccine has no toxic effects. The safety of this vac-
cine was established in a Phase-I study on healthy adult volunteers
and the results further conﬁrmed in phase II/III study. The efﬁcacy
of this vaccine was studied in endemic and non-endemic areas.
The sero-protection of the RS.JEV (Chinese vaccine, SA 14-14-2) is
77.56% at 28th day and has a decrease of 5% after 6months,whereas
JENVACR showing sero-protection of 98.67% at 28th day of single
dose vaccination and 99.78% after 56 days with a second dose vac-
cination. The Immunogenicity study has given 91% at 12 months,
67% at 18 months, 61% sero-protection even after 24 months.
Conclusion: The other vaccines available against JE virus are
live attenuated which is derived from the primary hamster kid-
ney cell culture whereas vaccine JENVACR manufactured by Bharat
Biotech is the ﬁrst VERO cell derived inactivated indigenous vac-
cine which induces high immunity against JE virus in adults and
children above one year and JENVACR is found stable for 2 years
at 2-8◦C is commercially available. Based on the results it is con-
cluded that JENVACR gives long-term protection against Japanese
encephalitis infection.
http://dx.doi.org/10.1016/j.ijid.2016.02.891
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Background: The National Primary Health Care Development
Agency (NPHCDA) with the collaboration of partners is developing
an enhanced routine immunization (RI) data collection module to
function within the National Health Management Information Sys-
tem (NHMIS) on the DHIS2 platform in order to capture and display
key RI indicators by dashboard. To commence implementation, a
need assessment survey was conducted in 4 LGAs and 16 HFs to
identify the capacity of the M &E, cold chain and LGA immuniza-
tion ofﬁcers(LIO) for data entry and reporting through DHIS2 and
to assess the availability of NHMIS reporting tools and RI-speciﬁc
data forms at the HFs and LGA level.
Methods & Materials: We purposively selected 4 LGAs (2 good
performing and 2 poor forming) based on NHMIS report on data
completeness, timeliness in 2014. We purposively selected 4 HFs
in each LGA, making 16HFs. We qualitatively assessed the needs
of the LGA and HFs. We administered semi-structured question-
naire and ODK Collect to LIO, CCO, RI focal person and ofﬁcer –in-
charge to collect data on routine immunization data access, use
and quality; stock management data recording; infrastructure and
system capacity; data review/analysis and feedback/action on data.
Descriptive data analysis was done using Microsoft excel 2010.
Results: A total of 12 HFs and 4 LGAs were assessed. Majority
(58.3%) of the health facilities reported that compilation ofmonthly
data report is done by HF ofﬁcer- in-charge. Majority (58.3% and
50%) of the health facilities reported that the staffs were trained on
routine immunization data recording and reporting respectively
in the past 12 months. Routine immunization micro plan was not
seen in all the HFs visited. Majority (75%) of the HFs receives data
recording and reporting tools for RI from the LGA primary health
care. Only 8.3% of the HFs makes use of the vaccine management
tools. Only 50% of the HFs takes data tools to outreach sessions.
Conclusion: The need assessment revealed a lot of gaps in RI
data management that needs to be addressed immediately before
the commencement of DHIS2 in the state. RI tools need to be
promptly distributed to all health facilities.
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